Driven to Cure, Inc. Donates an Additional $100,000 to the Foundation for the National Institutes of Health to Further Cutting-Edge Research on Rare Kidney Cancer
December 14, 2017 — Driven to Cure, Inc. has donated an additional $100,000 to the Foundation for the National Institutes of Health (FNIH) to further cutting-edge research on rare kidney cancer conducted by the National Cancer Institute (NCI) at the National Institutes of Health (NIH) Clinical Center. Over two years, Driven to Cure has donated a total of $300,000 to the FNIH to support the research of W. Marston Linehan, M.D., Chief of Urologic Surgery and the Urologic Oncology Branch, Center for Cancer Research at NCI. Dr. Linehan pioneered the study of the genetic basis of kidney cancer and is developing new approaches to treat multiple forms of the disease.
Andrew Lee, President and CEO of Driven to Cure, established the not-for-profit after being diagnosed two years ago, at age 19, with a rare kidney cancer known as HLRCC. Mr. Lee uses his two passions – cars and cancer awareness – to travel across the country attending car events to raise visibility and funding for rare cancers like HLRCC kidney cancer. Kidney cancer is among the 10 most common cancers in men and women, with the rate of new cases continuing to increase. In 2017, it is estimated that more than 63,000 people in the United States will be diagnosed with kidney and renal pelvis cancers and more than 14,000 individuals will die, according to NCI.
The Driven to Cure check presentation was made at the FNIH offices with Mr. Lee and Maria C. Freire, Ph.D., FNIH President and Executive Director. The event was attended by leadership from the NIH, including NIH Director Francis Collins, M.D., Ph.D., and Dr. Linehan.